 It was reissued in 2002 as RE 37,516, which surrendered the 5618845 patent.With pediatric exclusivity, this patent expired on April 6, 2015.On December 24, 2002, anticipating the expiration of exclusive marketing rights, generic drug manufacturers Mylan, Teva, Barr, and Ranbaxy applied to the FDA to market a generic form of modafinil.